Insider Selling: Cue Biopharma (NASDAQ:CUE) Insider Sells $265,664.61 in Stock

Cue Biopharma, Inc. (NASDAQ:CUE) insider Sumita Ray sold 8,829 shares of the business’s stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $30.09, for a total transaction of $265,664.61. Following the completion of the transaction, the insider directly owned 118,545 shares in the company, valued at $3,567,019.05. This trade represents a 6.93% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Cue Biopharma Trading Down 19.2%

CUE traded down $6.56 during trading on Monday, hitting $27.64. 305,202 shares of the company traded hands, compared to its average volume of 363,425. The company has a market cap of $116.09 million, a PE ratio of -1.02 and a beta of 2.47. The stock’s 50-day simple moving average is $29.50 and its two-hundred day simple moving average is $146.00. Cue Biopharma, Inc. has a 1 year low of $4.97 and a 1 year high of $45.50.

Cue Biopharma (NASDAQ:CUE) last announced its quarterly earnings results on Friday, August 14th. The company reported ($24.14) EPS for the quarter, missing the consensus estimate of ($1.69) by ($22.45). The company had revenue of $7.88 million during the quarter, compared to analysts’ expectations of $3.00 million. Cue Biopharma had a negative return on equity of 482.58% and a negative net margin of 435.83%.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on the company. Wall Street Zen downgraded Cue Biopharma from a “buy” rating to a “hold” rating in a research note on Saturday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cue Biopharma in a research note on Thursday. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Cue Biopharma has an average rating of “Sell”.

Institutional Trading of Cue Biopharma

A number of hedge funds and other institutional investors have recently bought and sold shares of CUE. Northwestern Mutual Wealth Management Co. increased its position in shares of Cue Biopharma by 730.0% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 83,000 shares of the company’s stock worth $57,000 after acquiring an additional 73,000 shares during the period. Squarepoint Ops LLC bought a new stake in Cue Biopharma during the 3rd quarter valued at $62,000. Stifel Financial Corp lifted its holdings in shares of Cue Biopharma by 25.4% in the 4th quarter. Stifel Financial Corp now owns 246,556 shares of the company’s stock worth $75,000 after buying an additional 50,000 shares during the period. Texas Capital Bank Wealth Management Services Inc grew its position in shares of Cue Biopharma by 1,231.2% during the 4th quarter. Texas Capital Bank Wealth Management Services Inc now owns 440,670 shares of the company’s stock worth $135,000 after buying an additional 407,568 shares in the last quarter. Finally, Boothbay Fund Management LLC grew its position in shares of Cue Biopharma by 15.3% during the 4th quarter. Boothbay Fund Management LLC now owns 704,297 shares of the company’s stock worth $215,000 after buying an additional 93,333 shares in the last quarter. Hedge funds and other institutional investors own 35.04% of the company’s stock.

Cue Biopharma Company Profile

Cue Biopharma is a clinical‐stage biotechnology company focused on the development of next‐generation immunotherapies for cancer and infectious diseases. The company’s proprietary platform, known as Cytokine Release & Targeting (CRT), is designed to deliver cytokine payloads directly to antigen‐specific T cells in order to enhance immune responses within targeted tissues. This approach aims to improve the therapeutic index of cytokine treatments by limiting systemic exposure and potentiating localized immune activation.

Founded in 2015 and headquartered in Cambridge, Massachusetts, Cue Biopharma has advanced multiple lead programs into early‐stage clinical studies.